Myricetin allosterically inhibits Dengue NS2B-NS3 protease as studied by NMR and MD simulations

Dengue NS2B-NS3 protease existing in equilibrium between the active and inactive forms is essential for virus replication, thus representing a key drug target. Here Myricetin, a plant flavonoid, was characterized to non-competitively inhibit Dengue protease. Further NMR study identified the protease residues perturbed by binding to Myricetin, which were utilized to construct the Myricetin-protease complexes. Strikingly, in the active form Myricetin binds a new allosteric site (AS2) far away from the active site pocket and allosteric site (AS1) for binding Curcumin, while in the inactive form it binds both AS1 and AS2. To decipher the mechanism for the allosteric inhibition by Myricetin, we conducted molecular dynamics (MD) simulations on different forms of Dengue NS2B-NS3 protease. Unexpectedly, the binding of Myricetin to AS2 is sufficient to disrupt the active conformation by displacing the characteristic NS2B C-terminal b- hairpin from the active site pocket. By contrast, the binding of Myricetin to AS1 and AS2 results in locking the inactive conformation. Therefore Myricetin represents the first small molecule which allosterically inhibits Dengue protease by both disrupting the active conformation and locking the inactive conformation. The results enforce the notion that a global allosteric network exists in Dengue NS2B-NS3 protease, which is susceptible to allosteric inhibition by small molecules such as Myricetin and Curcumin. As Myricetin has been extensively used as a food additive, it might be directly utilized to fight the Dengue infections and as a promising starting for further design of potent allosteric inhibitors.

DUAL FUNCTION OF ZIKA VIRUS NS2B-NS3 PROTEASE

Zika virus (ZIKV) serine protease, indispensable for viral polyprotein processing and replication, is composed of an NS2B polypeptide that associates with a proteolytic N terminal fragment of NS3 polypeptide (NS3pro) to form NS2B-NS3pro. The larger C-terminal fragment of NS3 polypeptide contains helicase activity. In the present study, we discovered that ZIKV NS2BNS3pro efficiently binds single-stranded (ss) RNA (Kd ~0.3 uM), suggesting that the protease may have a novel function. We tested an array of NS2B-NS3pro modifications and found that NS2B NS3pro constructs that adopt the recently discovered super-open conformation could not bind ssRNA. Likewise, stabilization of NS2B-NS3pro in the closed (proteolytically active) conformation by substrate-like inhibitors abolished ssRNA binding. Therefore, we suggest that ssRNA binding occurs when ZIKV protease adopts the open conformation, which could be modeled using dengue NS2B-NS3pro in the open conformation. ssRNA binding competes with ZIKV NS2B-NS3pro protease activity, likely by shifting the complex into the open conformation. Modeling of ZIKV NS3 helicase activity based on homologous crystal structures suggests that the open conformation of NS3pro domains provides a positively charged surface contiguous with the NS3 helicase domain. Such a positively charged surface is well poised to bind ssRNA, providing an explanation for the previously observed requirement of NS3pro for RNA processivity by viral helicase. Our structure-function analyses suggest that binding of ssRNA by the protease domain of NS3 is likely to be a universal feature of Flaviviridae, given the high level of homology between NS3 protease-helicase proteins in this family.

Virtual Screening of FDA Approved Drugs Library to Identify a Potential Inhibitor against NS2B-NS3 Protease of Yellow Fever Virus

Yellow fever is a neglected hemorrhagic disease with a high case fatality rate ranging between 25% and 50% for the hospitalized patients. Yellow fever disease is caused by a zoonotic pathogen known as yellow fever virus. This RNA virus is usually transmitted by mosquitos and it is considered endemic in the tropical regions of South America and Africa. Although an effective vaccine is available for yellow fever virus, no antiviral drug is yet licensed against the disease. Thus, yellow fever virus is still representing a re-emerging threat among unvaccinated individuals in endemic regions. The NS2B-NS3 protease seems to play an important role in yellow fever virus replication cycle. As such, the NS2B-NS3 protease may represent a potential target for structure-based drug design and discovery. In this direction, computational approaches like virtual screening can be utilized to hasten the design of novel antivirals and/ or repurposing an already FDA approved drugs. In this in silico study, an FDA approved drugs library was screened against NS2B-NS3 protease crystal of yellow fever virus. Then the best hits with least energy of binding and ability of hydrogen bonding with key residues of protease active site were then selected and submitted to molecular dynamics simulation. And throughout simulation interval, only Olsalazine was able to stay in close proximity to the active site of protease crystal with least average MM-PBSA binding energy as compared to Dantrolene, Belinostat and Linezolid. This indicates that Olsalazine may have the best capacity to bind to NS2B-NS3 protease and interfere with its activity.

A Critical Observation on the Design and Development of Reported Peptide Inhibitors of DENV NS2B-NS3 Protease in the Last Two Decades

: Dengue is one of the neglected tropical diseases, which remains a reason for concern as cases seem to rise every year. The failure of the only dengue vaccine, Dengvaxia®, has made the problem more severe and humanity has no immediate respite from this global burden. Dengue virus (DENV) NS2B-NS3 protease is an attractive target partly due to its role in polyprotein processing. Also, since it is among the most conserved domains in the viral genome, it could produce a broad scope of opportunities toward antiviral drug discovery in general. This review has made a detailed analysis of each case of the design and development of peptide inhibitors against DENV NS2B-NS3 protease in the last two decades. Also, we have discussed the reasons attributed to their inhibitory activity, and wherever possible, we have highlighted the concerns raised, challenges met, and suggestions to improve the inhibitory activity. Thus, we attempt to take the readers through the designing and development of reported peptide inhibitors and gain insight from these developments, which could further contribute toward strategizing the designing and development of peptide inhibitors of DENV protease with improved properties in the coming future.

Synthesis and Molecular Docking Studies of New Dispiropyrrolidines on West Nile Virus NS2B-NS3 Protease

West Nile virus (WNV) is among the other four flavivirus genus, rapidly spreading worldwide. The number of cases increases globally as there are no clinically available approved drugs and vaccines against this disease. Based on our previous finding related to a flavivirus, a series of spiropyrrolidine derivatives were regioselectively synthesized via [3+2]-cycloaddition reaction of three components between isatins, sarcosine, and (E)-3,5-bis (arylidene)-4-piperidones. The yield of synthesized compounds was in a range between 81–95%. The structures of all the synthesized compounds were characterized using FT-IR, 1D- and 2D-NMR, and HRMS. Molecular docking studies of spiropyrrolidines on NS2B-NS3 protease were done to understand and explore the ligand-receptor interactions and hypothesize the drug's refinements. The inhibition of NS2B-NS3 protease has been considered a promising strategy because this enzyme is responsible for the viral replication process. Among them, compound 5c shows an excellent binding affinity with ‒7.71 kcal/mol free binding energy and an inhibition constant of 1.73 μM. It also showed the binding orientation into the active site of WNV NS2B-NS3 protease on Asn84, Tyr1161, Gly1151, and Gly1153.

A mutation-mediated evolutionary adaptation of Zika virus in mosquito and mammalian host

Zika virus (ZIKV) caused millions of infections during its rapid and expansive spread from Asia to the Americas from 2015 to 2017. Here, we compared the infectivity of ZIKV mutants with individual stable substitutions which emerged throughout the Asian ZIKV lineage and were responsible for the explosive outbreaks in the Americas. A threonine (T) to alanine (A) mutation at the 106th residue of the ZIKV capsid (C) protein facilitated the transmission by its mosquito vector, as well as infection in both human cells and immunodeficient mice. A mechanistic study showed that the T106A substitution rendered the C a preferred substrate for the NS2B-NS3 protease, thereby facilitating the maturation of structural proteins and the formation of infectious viral particles. Over a complete “mosquito-mouse-mosquito” cycle, the ZIKV C-T106A mutant showed a higher prevalence of mosquito infection than did the preepidemic strain, thus promoting ZIKV dissemination. Our results support the contribution of this evolutionary adaptation to the occasional widespread reemergence of ZIKV in nature.